/ /

Ophthalmology

Intravitreal brimonidine holds promise for slowing GA growthBrimonidine Drug Delivery System (Brimo DDS) in an intravitreally administered, sustained-release implant (Allergan) shows promise as a treatment for geographic atrophy (GA), secondary to age-related macular degeneration in a phase IIa clinical trial.
Novel brolucizumab fosters as real-world alternative for nAMDTopline results from phase III studies investigating intravitreal brolucizumab (Novartis) for treatment of neovascular age-related macular degeneration (nAMD) support the potential of this novel anti-VEGF antibody to meet the real-world need for an alternative agent with a sustainable therapeutic regimen.
IOL-telescope may improve vision for patients with advanced maculopathiesTake-Home Message: The Telescopic Intra-Ocular Lens for Visually Impaired People Revolution system is promising to improve the vision in patients with maculopathies.
Why ophthalmologists are easy prey for cybercriminalsA perfect storm is brewing that may make ophthalmologists and office staff, with networked equipment, easy targets for cyber criminals. In a matter of days, cyber criminals can infect computers around the world. Sure, you can pay the ransom, but HIPAA fines and consultant fees, recovering from the damage to your reputation, loss of patients, and all the time and energy lost could bankrupt your practice.
Aflibercept helps in ME patients with DR after cataract surgeryPatients with diabetic retinopathy have a high risk of developing macular edema after cataract surgery. Intravitreal injections of aflibercept might result in fewer patients developing macular edema in this patient population.
ALG-1001: Turning off the machinery of angiogenesisALG-1001 (Luminate, Allegro Ophthalmics) has a number of different mechanisms of action that benefit patients chronically treated with anti-vascular endothelial growth factor drugs and those who are treatment naïve.
AO imaging offers novel data for understanding retinal diseaseAdaptive optics (AO) is providing new insights about retinal structure and may help to identify potential areas for treatment of retinal diseases, said Mina Chung, MD.
Role of corticosteroids uncertain in AMD managementThere is no doubt that inflammation is a component of age-related macular degeneration (AMD), and yet the role of corticosteroid treatment in the management of eyes with AMD remains uncertain, said Marc de Smet, MD, PhD.
New therapies needed for allergy symptoms, quality of lifeHalf of patients with ocular allergies report experiencing symptoms year-round. While nearly all of them take eye drops to treat their symptoms, the majority report limited or no effect from over-the-counter drops, according to a new survey. The results suggest that new treatment approaches would improve both symptoms and quality of life.
P.S. Use this cost-effective marketing tactic to increase end-of-year profitsWhen you do not have enough money or time, a well-worded post script can be your best friend. Whether you are the new doctor who doesn’t have a large database or the kind-hearted provider who accepts all those low-paying plans and really can’t afford the estimated 60 cents per unit cost of a fall postcard campaign, please consider adding a P.S. to emails and a red-ink P.S. to all patient-directed, routine postal pieces.